1. 1381PDGefitinib with or without pemetrexed in nonsquamous (NS) non-small cell lung cancer (NSCLC) with EGFR mutation (mut): Final overall survival (OS) results from a randomized phase II study. (23rd October 2018) Authors: Yang, J C-H; Cheng, Y; Murakami, H; Yang, P-C; He, J; Nakagawa, K; Kang, J H; Kim, J-H; Wnag, X; Enatsu, S; Puri, T; Orlando, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1392PDose-determination results from a phase Ib/II study of ceritinib (CER) + ribociclib (RIB) in ALK-positive (ALK+) non-small cell lung cancer (NSCLC). (23rd October 2018) Authors: Santoro, A; Su, W-C; Navarro, A; Simonelli, M; Yang, J C-H; Ardizzoni, A; Barlesi, F; Kang, J H; Didominick, S; Abdelhady, A; Goswami, B; Crystal, A; Felip, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 373PMolecular profiling of non-small cell lung cancer (NSCLC) in Asia with targeted next-generation sequencing (NGS): Interim analysis of a co-operative group study (ATORG-001). (24th November 2019) Authors: Tan, A C; Loong, H; Ho, G F; Seet, A; Chiam, B; Cheah, D Q; Tan, G S; Lim, K H; Yang, J C-H; Mok, T S K; Kim, D-W; Tan, D S W Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 477OTepotinib plus gefitinib in patients with MET-amplified EGFR-mutant NSCLC: Long-term outcomes of the INSIGHT study. (24th November 2019) Authors: Park, K; Zhou, J; Kim, D-W; Ahmad, A R; Soo, R A; Bruns, R; Straub, J; Johne, A; Scheele, J; Yang, J C-H; Wu, Y-L Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 489POverall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study. (24th November 2019) Authors: Hochmair, M J; Morabito, A; Hao, D; Yang, C-T; Soo, R A; Yang, J C-H; Gucalp, R; Halmos, B; Wang, L; Märten, A; Cufer, T Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 531TiPCANOPY-A: A phase III, placebo-controlled study of canakinumab as adjuvant therapy in patients (pts) with surgically resected NSCLC. (24th November 2019) Authors: Cho, B C; Chang, G-C; Kim, Y-C; Geater, S; Saeteng, S; Yang, C-T; Goto, Y; Lu, S; Ardizzoni, A; Barlesi, F; De Marchi, P; Paz-Ares, L; Spigel, D R; Thomas, M; Garon, E B; Leung, M; Baum, J; Zewen, Z; Mookerjee, B; Yang, J C-H Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 533TiPCANOPY-2: A phase III, placebo-controlled study of canakinumab with or without docetaxel in patients (pts) with NSCLC previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy (Ctx). (24th November 2019) Authors: Lim, D; Goto, Y; Cho, B C; Kaneda, H; Kang, J-H; Kim, S-W; Chiu, C-H; Yang, J C-H; Su, W-C; Obyrne, K; Papadimitrakopoulou, V; Reck, M; Malet, I; Mookerjee, B; Zewen, Z; Rodriguez, L Paz-Ares Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 536TiPINSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study. (24th November 2019) Authors: Yang, J C-H; Ellers-Lenz, B; Straub, J; Johne, A; Wu, Y-L Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. LBA1Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial. (24th November 2019) Authors: Camidge, R; Kim, H R; Ahn, M-J; Yang, J C-H; Han, J-Y; Hochmair, M J; Lee, K H; Delmonte, A; Garcia Campelo, M R; Kim, D-W; Griesinger, F; Felip, E; Califano, R; Spira, A; Gettinger, S; Tiseo, M; Ni, Q; Zhang, P; Popat, S Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. LBA2TATTON expansion cohorts: A phase Ib study of osimertinib plus savolitinib in patients (pts) with EGFR-mutant, MET-positive NSCLC following disease progression on a prior EGFR-TKI. (24th November 2019) Authors: Han, J-Y; Sequist, L V; Ahn, M-J; Cho, B C; Yu, H; Kim, S-W; Yang, J C-H; Lee, J S; Su, W-C; Kowalski, D; Orlov, S; Cantarini, M; Verheijen, R B; Mellemgaard, A; Frewer, P; Ou, X; Oxnard, G Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗